Docs Deborah A
—- Market cap
- —
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: Docs Deborah A stock price vs RCUS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RCUS's multiple
Needs EPS (TTM), RCUS P/E.
Implied fair value · at Docs Deborah A's multiple
Needs EPS (TTM) is negative, Docs Deborah A P/E.
Engine logicDocs Deborah Avalued onRCUS’smultiple
Metric by metric
Where each company leads, and how wide the gap is.
Snapshot Sep 4, 4:00 PM ET
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: Docs Deborah A Latest annual filing · RCUS FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 97% equity / 3% debt · EV / Revenue 14.79x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DOCS DEBORAH A · implied price per share
Reporting currency could not be verified.
Arcus Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Docs Deborah A · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
0.16x
Net debt / EBITDA
Leverage against operating earnings
—
0.36x
Cash and equivalents
Liquid reserves on the balance sheet
—
$222.00M
Total debt
Interest-bearing obligations outstanding
—
$99.00M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.